|
Parameters
|
Subtype
|
Recurrence patterns
|
Pathological total response
| |
|---|
|
Operation type
| | |
pCR
|
Non-pCR
|
P value
|
|---|
|
(N = 91)
|
(N = 524)
|
|---|
|
Mastectomy
|
HR + /HER2-
|
LRR
|
1 (9.1%)
|
25 (9.8%)
|
> 0.999
|
|
(N = 615)
|
(N = 266)
|
No LRR
|
10 (90.9%)
|
230 (90.2%)
|
| |
HR + /HER2 +
|
LRR
|
0
|
11 (10.8%)
|
0.12
|
| |
(N = 130)
|
No LRR
|
28 (100%)
|
91 (89.2%)
|
| |
HR−/HER2 +
|
LRR
|
1 (2.5%)
|
15 (14.3%)
|
0.071
|
| |
(N = 145)
|
No LRR
|
39 (97.5%)
|
90 (85.7%)
|
| |
HR−/HER2−
|
LRR
|
2 (16.7%)
|
11 (17.7%)
|
> 0.999
|
| |
(N = 74)
|
No LRR
|
10 (83.3%)
|
51 (82.3%)
|
|
Conserving breast surgery
|
HR + /HER2−
|
LRR
|
1 (6.3%)
|
6 (4.4%)
|
0.546
|
|
(n = 432)
|
(N = 153)
|
No LRR
|
15 (93.7%)
|
131 (95.6%)
|
| |
HR + /HER2 +
|
LRR
|
3 (7.9%)
|
5 (7.2%)
|
> 0.999
|
| |
(N = 107)
|
No LRR
|
35 (92.1%)
|
64 (92.8%)
|
| |
HR−/HER2 +
|
LRR
|
4 (8.3%)
|
9 (25.0%)
|
0.037
|
| |
(N = 84)
|
No LRR
|
44 (91.7%)
|
27 (75.0%)
|
| |
HR−/HER2−
|
LRR
|
0
|
10 (20.4%)
|
0.002
|
| |
(N = 88)
|
No LRR
|
39 (100%)
|
39 (79.6%)
|
- HR hormone receptor, HER-2 human epidermal growth factor receptor 2, LRR locoregional recurrence, pCR pathological complete response
